LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised

LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.

Zacks Investment Research • Aug 6, 2026

LivaNova Q2 Earnings Call Highlights

LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure.

MarketBeat • Aug 5, 2026

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared to the prior-year period Second-quarter U.S. GAAP diluted earnings per share of $1.93 and adjusted diluted earnings per sh.

Business Wire • Aug 5, 2026

LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.05 per share a year ago.

Zacks Investment Research • Aug 5, 2026

LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Aug 5, 2026

LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?

LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Aug 5, 2026

3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdles

GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.

Zacks Investment Research • Jul 17, 2026

LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?

LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Jul 7, 2026

LivaNova to Announce Second-Quarter 2026 Results

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To lis.

Business Wire • Jun 24, 2026